

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北斗嘉藥業股份有限公司
BAYTACARE PHARMACEUTICAL CO., LTD.*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8197)

**PROPOSED CHANGE OF REGISTERED ADDRESS
AND
PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION**

TEMPORARY CHANGE OF REGISTERED ADDRESS

Due to PRC regulatory requirements, the registered address of the Company shall be temporarily changed from “No.3, No. 2 Road, Jilin Hi-Tech Development Zone, Jilin City, Jilin Province, the People’s Republic of China” to “Shops B2-1-101, 102, 103, 104, Qingqingjiayuan, Buji, Longgang District, Shenzhen” in May 2019 (the “**Temporary Change of Registered Address**”).

PROPOSED CHANGE OF REGISTERED ADDRESS

After the Temporary Change of Registered Address, the Board proposes to change the registered address of the Company (the “**Proposed Change of Registered Address**”) to “Room 601, Longyuan Chuangzhan Building, No. 2010 Baoan South Road, Luohu District, Shenzhen, Guangdong Province, China”, subject to the following conditions:

- (1) the passing of an ordinary resolution by the Shareholders at the forthcoming annual general meeting of the Company (the “**AGM**”) to approve the Proposed Change of Registered Address; and
- (2) any necessary approval of the relevant PRC authorities in relation to the Proposed Change of Registered Address being obtained.

The relevant filing with relevant PRC authorities will be made after the passing of the relevant ordinary resolution at the AGM. Subject to the satisfaction of the conditions set out above, the Proposed Change of Registered Address will take effect from the date of completion of the registration of change in its registered address with the relevant industry and commerce bureau in the PRC.

PROPOSED AMENDMENT TO THE ARTICLES OF ASSOCIATION

Taking into account the Proposed Change of Registered Address of the Company, the Board proposes to make amendment to the articles of association of the Company (the “**Proposed Amendment to the Articles of Association**”).

Article 3:

Existing Article

Domicile of the Company: No.3, No.2 Road, Jilin High-tech Development Zone, Jilin Province, the PRC

Postal Code: 132013

Telephone: 0432-64641900

Facsimile: 0432-64879802

Amended Article

Domicile of the Company: Room 601, Longyuan Chuangzhan Building, No. 2010 Baoan South Road, Luohu District, Shenzhen, Guangdong Province, China

Postal Code: 518001

Telephone: 0755-82327716

GENERAL

A notice of AGM and a circular containing, among other matters, details of the Proposed Change of Registered Address and the Proposed Amendment to the Articles of Association will be despatched to the Shareholders on 15 May 2019.

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd.*
Executive Director
Cui Bingyan

Shenzhen, People's Republic of China, 14 May 2019

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Chen Youfang and Zhu Tianxiang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company’s website at www.baytacare.com from the date of this announcement.

** for identification purposes only*